NASDAQ · ABOS
Acumen Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for ABOS has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Fintel- RTTNews · Oct 27, 6:24 AM EDTAcumen Q3 Loss Narrows; Alzheimer's Trial Results Due November 2026(RTTNews) – Acumen Pharmaceuticals, Inc. (ABOS) reported on Monday a narrower third-quarter net loss and said it expects Phase 2 ALTITUDE-AD topline results in November 2026.
- RTTNews · Oct 26, 3:25 PM EDTThree Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout(RTTNews) – Shares of several biotech companies moved sharply higher following corporate and clinical developments. Surgery Partners surged on reports of a late-stage buyout talks with Bon Secours Mercy Health, Xencor rallied on updated Phase 1 data for XmAb819 in kidney cancer,
- The Motley Fool · Oct 26, 12:12 PM EDTAcumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Oct 26, 10:02 AM EDTAcumen Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat Week in Review – 7/17 – 7/21Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alz
- Fintel · Oct 26, 9:34 AM EDTAcumen Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Targets November 2026 for ALTITUDE-AD Topline ResultsAcumen Pharmaceuticals, Inc. reported its financial results for the third quarter of 2026 and provided updates on its clinical pipeline. The Company expects to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Al
- BNK Invest · Oct 20, 12:24 PM EDTTuesday Sector Leaders: Biotechnology, DrugsIn trading on Tuesday, biotechnology shares were relative leaders, up on the day by about 4.2%. Leading the group were shares of Myriad Genetics, up about 37.5% and shares of Larimar Therapeutics up about 14.4% on the day. Also showing relative strength are drugs shares, up on
- Zacks · Sep 21, 12:40 PM EDT4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayFour biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
- RTTNews · Aug 14, 6:59 AM EDTAcumen's Q2 Loss Narrows; Topline Phase 2 Data For Alzheimer's Drug Sabirnetug In Late '26(RTTNews) – Acumen Pharmaceuticals Inc. (ABOS), a clinical-stage biopharmaceutical company, on Wednesday announced second quarter financial results and noted a lower net loss owing to reduced research and development (R&D) expenses.
- MarketBeat · Aug 12, 9:03 AM EDTAcumen Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat Week in Review – 7/17 – 7/21Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oli
- Zacks · Jul 31, 9:40 AM EDTIs Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
- Zacks · Jul 15, 12:00 PM EDTAll You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to BuyAcumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jul 15, 9:40 AM EDTAre Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Acumen Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.